📰 International Study Evaluating News
International Study Evaluating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from International Study Evaluating. Real-time updates on events, politics, business and more.
November 13, 2023
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...
October 23, 2023
NORCROSS, Ga., Oct. 23, 2023 -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C....
October 14, 2022
14.10.2022 - NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October ...
October 12, 2022
NORCROSS, Ga., Oct. 12, 2022 -- Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug application for... | October 12, 2022
July 26, 2022
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 ...
November 5, 2021
New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic...
April 14, 2021
Home / Top News / Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy Combination therapy with belapectin suggests a better objective response rate w...